Comparison of Hormonal Response to a Mixed-Meal Tolerance Test After Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy With Duodenojejunal Bypass in Patients With Super Morbid Obesity
Recruiting now · Not applicable
Conditions studied: Bariatric Surgery, Hormonal Response, Post Bariatric Hypoglycemia
In brief
Obesity is a major global health problem. Bariatric surgery is the most effective treatment, leading to substantial weight loss and improvement in obesity-related comorbidities. The most commonly performed procedures are Laparoscopic Roux-en-Y gastric bypass (LRYGB) and Laparoscopic sleeve gastrectomy (LSG). LRYGB is typically selected for patients with a BMI exceeding 50 kg/m2. Recently, LSG with duodenojejunal bypass (LSG-DJB) has been introduced. To date, no randomized controlled trial has compared LRYGB and LSG-DJB in patients with super morbid obesity, particularly regarding postoperative hormonal responses. This study aims to address this gap. If LSG-DJB results in a lower incidence of post-bariatric hypoglycemia than LRYGB, it would support its clinical benefit. Evaluation of GLP-1, GIP, glucagon, and insulin responses will clarify mechanisms underlying weight loss and postprandial glycemic changes.
Key facts
- Study ID
- NCT07747779
- Run by
- Chulalongkorn University
- People needed
- 32
- Starts
- 2024-08-08
- Expected to finish
- 2027-07-31
- Last updated by the study team
- 2026-08-06
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with an indication for bariatric surgery
- BMI 50-60 kg/m2
- Patients who are motivated to lose weight but have not achieved successful weight reduction despite optimal medical therapy and exercise under physician supervision
You may not qualify if…
- Patients with diabetes mellitus
- Patients with severe comorbid conditions that contraindicate surgery, such as advanced heart disease or chronic kidney failure
- Patients with a history of previous bariatric surgery
- Patients with gastroesophageal reflux disease refractory to medical therapy, large hiatal hernia, or endoscopic findings of reflux esophagitis grade C or D, or Barrett esophagus
- Patients with psychiatric disorders that impair eating behavior control
- Patients with a history of pancreatitis, pancreatic disease, or inflammatory bowel disease
- Patients who have used steroids or GLP-1 receptor agonists within the past 2 months
Where it is running
- King Chulalongkorn Memorial Hospital — Pathum Wan, Bangkok, Thailand (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.